stockportfolio.pro
Aurinia Pharmaceuticals Inc. (AUPH)
Healthcare · Biotechnology · NasdaqGM
Aurinia Pharmaceuticals Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $463,000 | $318,000 | $50.12M | $45.60M | $134.03M | $175.51M | $235.13M | $283.06M |
| Gross profit | — | — | — | $44.51M | $128.37M | $161.37M | $206.88M | $250.39M |
| Net income | $-53.08M | $-88.39M | $-102.68M | $-180.97M | $-108.18M | $-78.02M | $5.75M | $287.20M |
| Net margin | -11464.1% | -27794.0% | -204.9% | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
Source: Aurinia Pharmaceuticals Inc. SEC filings (10-K).
What growth is priced into AUPH stock?
At today's market cap of $2.03B, Aurinia Pharmaceuticals Inc. is priced for free-cash-flow growth of about 3.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $135.41M from the FY ending 2025-12-31). For comparison, revenue 41.4%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 8 years of Aurinia Pharmaceuticals Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AUPH in your portfolio →
Aurinia Pharmaceuticals Inc. financial history by metric
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc. — frequently asked questions
What is Aurinia Pharmaceuticals Inc.'s revenue?
Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $283.06M for fiscal year 2025, up 20.4% from the prior year, according to its SEC filings.
Is Aurinia Pharmaceuticals Inc. profitable?
Yes. AUPH earned net income of $287.20M in fiscal 2025, a net margin of 101.5%.
What is AUPH's P/E ratio?
Aurinia Pharmaceuticals Inc. trades at a price-to-earnings ratio of about 7.3 based on the latest data in our nightly-refreshed cache.
How fast is Aurinia Pharmaceuticals Inc. growing?
AUPH's revenue grew at roughly 41.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Aurinia Pharmaceuticals Inc. have?
As of fiscal year 2025, AUPH carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Aurinia Pharmaceuticals Inc.'s gross margin?
AUPH's gross margin was 88.5% in fiscal 2025 — gross profit of $250.39M on revenue of $283.06M.
What is Aurinia Pharmaceuticals Inc.'s market cap?
Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of about $2.03B, based on the latest data in our nightly-refreshed cache.
When does Aurinia Pharmaceuticals Inc.'s fiscal year end?
AUPH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into AUPH stock?
At today's market cap of $2.03B, Aurinia Pharmaceuticals Inc. is priced for free-cash-flow growth of about 3.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $135.41M from the FY ending 2025-12-31). For comparison, revenue 41.4%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Aurinia Pharmaceuticals Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.